The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset

MALCOLM PROUDFOOT1, ASHLEY JONES2, KEVIN TALBOT1, AMMAR AL-CHALABI2 & MARTIN R. TURNER1

1Nuffield Department of Clinical Neuroscience, University of Oxford and 2Department of Clinical Neuroscience, Institute of Psychiatry, King’s College London, London SE5 8AF, UK

Abstract
The reduction in ALS Functional Rating Score (ALSFRS) from reported symptom onset to diagnosis is used to estimate rate of disease progression. ALSFRS decline may be non-linear or distorted by drop-outs in therapeutic trials, reducing the reliability of change in slope as an outcome measure. The PRO-ACT database uniquely allows such measures to be explored using historical data from negative therapeutic trials. The decline of functional scores was analysed in 18 pooled trials, comparing rates of decline based on symptom onset with rates calculated between interval assessments. Strategies to mitigate the effects of trial drop-out were considered. Results showed that progression rate calculated by symptom onset underestimated the subsequent rate of disability accumulation, although it predicted survival more accurately than four-month interval estimates of $d_{ALSFRS}$ or $d_{FVC}$. Individual ALSFRS and FVC progression within a typical trial duration were linear. No simple solution to correct for trial drop-out was identified, but imputation using $d_{ALSFRS}$ appeared least disruptive. In conclusion, there is a trade-off between the drive to recruit trial participants soon after symptom onset, and reduced reliability of the ALSFRS-derived progression rate at enrolment. The need for objective markers of disease activity as an alternative to survival-based end-points is clear and pressing.

Key words: Motor neuron disease, survival, prognosis, modelling; clinical trial

Introduction
ALS is a heterogeneous condition with multiple pathological pathways culminating in overlapping disease phenotypes (1). Despite this complexity, clinical and demographic characteristics readily assessed at time of presentation can inform prediction of disease progression (2–7). However, even within clinically-defined subtypes (8) or genotypes (9,10), progression rates remain relatively dispersed. Accurate characterization of multimodal biomarkers that can capture the range of the pathogenic process in ALS remains a priority (11).

The successful application of future therapies for ALS depends upon meaningful evaluation against valid and relevant outcome measures. Clinical severity scores, whether measured by self-reported loss of function scales (most commonly the revised ALS Functional Rating Score, ALSFRS-R), or by objective structured assessment (e.g. the Appel Scale), have been reported to decline in a largely linear fashion (12–14). Not all studies concur, in particular early stages of the illness have been characterized by accelerated functional decline (15), although this effect is at least partially mitigated by restricting analysis to a survivor subgroup (7). The measured rate of decline remains an important predictor of functional and mortality outcomes (16,17). Change in ALSFRS over time ($d_{ALSFRS}$) (Figure 7 in (18)) can serve as an approximate measure of disease severity and cohort studies have demonstrated $d_{ALSFRS}$ to predict survival (19), encouraging its inclusion as a covariate in the analysis of interventional studies. Irrespective of function, ventilatory failure is the typical mode of death in ALS, and forced vital capacity (FVC) measurement complements the ALSFRS in both prediction of survival and representation of disease progression (20–23).
The self-reported date of symptom onset is a critical framing heuristic in ALS that is taken as time-zero for calculation of \( \delta \text{ALSFRS} \) at the first clinical encounter. This estimation is subject to recall bias, and typically relies on perception of first actual weakness, which can (albeit in a minority) neglect onset in cognitive or respiratory domains and more non-specific symptoms such as cramp or fasciculation. \( \delta \text{FVC} \) may similarly be estimated at the first clinical encounter by considering time-dependent deviation from predicted FVC based upon age, height and gender (13,24).

Repeated assessment of patients is inherent to most clinical trials in ALS, and permits repeated calculation of \( \delta \text{ALSFRS} \). Longitudinal analysis of disability progression also serves to expose selective withdrawal from trials of the most disabled participants. This potential confound is a complicating factor in the interpretation of clinical trial outcomes but prospective \( \delta \text{ALSFRS} \) extrapolation may assist to mitigate drop-out bias. Using pooled data from therapeutic trials in ALS, we sought to compare subjectively-reported symptom onset with that calculated from repeated-interval derivations of \( \delta \text{ALSFRS} \) extrapolated backwards.

**Methods**

Demographic and clinical data from 17 therapeutic trials comprising 4752 records in PRO-ACT were included in the analysis on the basis of at least two time-separated assessments of disability (25). The majority of PRO-ACT records contain only original ALSFRS, rather than revised (ALSFRS-R) scores. Therefore, for harmonization, 882 records were converted from ALSFRS-R to ALSFRS by collapsing across the respiratory subscore (discounting orthopnoea). A total of 42,584 assessments across a mean individual maximum time-span of 11.1 (5.4) months were analysed, averaging 8.8 (3.6) assessments per person.

Time elapsed from symptom onset was recorded for over 99% of the included participants, thus defining reported disease duration. The \( \delta \text{ALSFRS} \) (points decline per month) could therefore be calculated as either drop in ALSFRS from 40 divided by disease duration, or by subtraction of time-separated ALSFRS assessments divided by the inter-visit time-interval. Calculated \( \delta \text{ALSFRS} \) was then used to extrapolate back to the date at which ALSFRS = 40, i.e. no disability.

This approach was then validated using FVC data and ALSFRS-R scores. 4168 records in PRO-ACT include at least two FVC measurements separated by at least one month. The smaller portion of PRO-ACT records with ALSFRS-R was supplemented by 217 individual longitudinal data records from the Lithium Carbonate in ALS (LiCALS) study, resulting in 1709 individual records suitable for analysis, that demonstrated incremental disability over a median time-interval of 11.0 months.

Within the PRO-ACT database 1863 individual records included mortality data, and from this subset only 464 remained alive at the last census. Hazard curves were constructed from both the entire population and the mortality subset to represent time-dependent risk of death or significant disability (defined as ALSFRS \( \leq 21 \), the median final assessment ALSFRS across participants).

Trial drop-out mitigation methods appraised included the re-assignment of missing values with either (1) imputed values of ALSFRS based on linear extrapolation using \( \delta \text{ALSFRS} \) calculated from the first assessment to the last available assessment, or (2) ALSFRS values carried forward unchanged from the last available assessment for that participant, with or without (3) assignment of ALSFRS = 0 if the participant died prior to the planned assessment.

Data were analysed using Matlab and SPSS 21. Paired \( t \)-tests compared alternative measures for individual patients and Spearman’s rho was used for correlations to minimize the effect of non-normative data. Mean value was followed by standard deviation in parenthesis.

**Results**

At trial enrolment, the median length of disease duration was 18.7 months (mean 22.5 (14.5)). The mean rate of disease progression since symptom onset was 0.59 (0.49) per month. A wide spread of progression rate was noted, with positive skew (Figure 1).

Averaging across participants the ALSFRS dropped over each individual’s maximum-recorded interval during the trial from 29.9 (5.7) to 21.2 (8.6) (Figure 2). This variability reflected both inter-individual diversity in progression rates and inter-trial differences in length of follow-up.

Longitudinal analysis was complicated by declining participation over time. Patients with less rapidly progressive disease were increasingly over-represented as follow-up extended. Global PRO-ACT ALSFRS averages superficially suggested a deceleration in the rate of disability accumulation in the later stages of disease durations. However, analysis of progression curves divided into sub-groups of survivors at predefined yearly intervals, revealed a linear progression (linear fit \( r^2 = 0.998 \), two-year survivor group) in disability over the study period (Figure 3). Analysis of the FVC data confirmed linear decline (\( r^2 = 0.992 \)) in respiratory function over time within survivor subgroups (Figure 4).

The apparent dramatic slowing in disability accumulation in the later stages of ALS appeared not to be a confounding feature specific to the ALSFRS scale, but rather to be mediated by
selective loss to the trial through death or withdrawal of those with more rapidly progressive disease. This interpretation was reinforced by inspection of rates of disability accumulation as calculated across intervals between trial assessments. These rates remained constant within subgroups of survivors to specified end-points (Figure 5).

The rate of disease progression as measured across each given individual’s maximum assessment interval was also broad with positive skew, mean 0.95 (0.96) (Figure 6).

Considering the impact of including patient-reported symptom onset data in the calculation of disease progression rates, direct comparison was possible in 4649 individuals for whom symptom onset dates were available. This revealed the maximum interval ALSFRS measurement-derived rate to be faster (median difference 0.24 month$^{-1}$, mean 0.37 (0.93)) than that estimated by drop in ALSFRS from symptom onset to trial enrolment ($p<0.001$, $t(4648) = 27.10$). A correlation was nonetheless still noted between the rates as calculated by differing methods ($\rho = 0.421$, $p<0.001$).

Figure 1. The rate of disease progression in participants at the time of trial enrolment. Calculated as (40–enrolment ALSFRS)/months from symptom onset.

Figure 2. The spread of disability levels as measured by ALSFRS at both the time of trial enrolment and at the last available time-point (trial termination) for each individual.
Excluding 354 individuals who did not accumulate any disability over the course of study participation, the time-point of ALSFRS = 40 was estimated by extrapolating backwards from the final assessment, using the rate of progression calculated across the maximum assessment interval, under the assumption of linearity. This estimated time-point did not coincide precisely with reported symptom onset ($p < 0.001$). Functional disability severe enough to register on the ALSFRS followed symptom onset by a median lag of 5.8 months. This interval between 1) the time-point that a patient first perceived a motor abnormality, and 2) the temporal estimation of when functional disability accumulation was first detectable on the ALSFRS scale, was found to be smaller the further into disease duration that trial enrolment occurred (Figure 7). This predictive accuracy was, however, also dependent upon the individual’s rate of disease progression, with the largest inaccuracy for those with slowest disease progression (‘funnel’ appearance to scatterplot Figure 8).

The validation data analysis using the ALSFRS-R described a decline from a median of 39 at trial entry to 29 at final assessment. Disability accumulation curves over time demonstrated a similar

Figure 3. Accumulation of disability over time appears to slow over the course of the trial (dotted line), but declining numbers of participants are noted over time. Progression within groups of survivors to defined end-points appears more linear.

Figure 4. Decline in FVC mirrors ALSFRS in demonstrating apparent slowing across all participants but linear decline within survivor sub-groups.
flattening of progression rates, dependent on selective loss to follow-up (Supplementary Figure 1). The time-point of first significant disability milestone (ALSFRS-R = 48) was again estimated by back-extrapolation from the final assessment point using maximum interval \( \Delta \text{ALSFRS-R} \). The median time-lag from reported symptom onset was 8.3 months. Disability accumulation, regardless of scale choice, was subject to wide variability between individuals (Supplementary Figure 2).

The median survival within the PRO-ACT mortality subset was 32.4 months from symptom onset, while median survival without significant disability was 24.4 months. Ongoing active participation in the clinical trials was noted to decline rapidly beyond 25 months after trial onset. In accordance with the above findings, the risk of acquiring significant disability appeared to plateau and then decline (Figure 9). Restricting the hazard ratio analysis to the survivor subset continued to demonstrate a plateau in mortality risk at approximately 50 months after symptom onset. Mortality was typically preceded by significant disability (Figure 10). Both FVC and ALSFRS at the initial visit were predictive of subsequent mortality, but symptom onset-anchored initial rates of decline

Figure 5. The rate of disease progression during the trial (calculated between assessment intervals) does not alter if analysis restricted to survivors. Including all participants (dotted line), the rate of disease progression appears to fall as more rapidly progressive patients drop out.

Figure 6. The rate of disability accumulation over the course of the trial, ignoring the time-period from symptom onset to trial enrolment.
improved predictive accuracy (strongest correlation with survival was initial \( \delta \text{ALSFRS} \), rho = 0.6, log-log transform displayed), and still outperformed the interval \( \delta \text{ALSFRS} \) and \( \delta \text{FVC} \) derived over the first four months of trial participation (Figure 11).

Comparative appraisal of drop-out mitigation options revealed the last-observation-carried-forward (LOCF) technique to only minimally correct the apparent flattening in the \( \delta \text{ALSFRS} \) slope, whereas a more linear progression was revealed using slope-imputed values (Figure 12). Assigning \( \text{ALSFRS} = 0 \) to assessments falling after the confirmed date of a participant’s death resulted in a disproportionate acceleration of apparent ALSFRS decline unless the remaining absent values were re-assigned by imputation or LOCF (Figure 13).

**Discussion**

The key findings of this study were:

- Initial rates of ALS progression calculated from recalled date of symptom onset tended to
underestimate the subsequent rate of disability progression.

- The recalled symptom onset-anchored rate of progression nevertheless predicted survival more accurately than four month interval estimates of δALSFRS or δFVC.
- As the denominator of time was increased, symptom onset-anchored progression rate improved in its predictive power of future progression rate.
- After comparatively slower initial progression from symptom onset, individual ALSFRS and FVC progression during a typical trial duration appeared to be linear.

- No simple solution to correcting for trial dropout was identified, but imputation using δALSFRS appeared least disruptive.

These findings are relevant for future studies that intend to take account of δALSFRS in participant enrolment, consideration of covariables, or endpoint selection. These data support the application of the longest possible time-intervals as denominator in calculation of δALSFRS to minimise chance variation. These data also support previous findings that the rate of disease progression calculated from symptom onset carries valuable prognostic information (13,16,18,19).

Figure 9. Hazard ratio of progression to significant disability (ALSFRS $\leq 21$, the median final ALSFRS recorded) appears to plateau and diminish with time. Complicated by declining trial participation.

Figure 10. Hazard ratios for both disability and death appear to plateau despite restricting analysis to participants with mortality data at census.
Figure 11. FVC and ALSFRS correlations with mortality, measured as initial absolute values, initial rates and interval rates. Initial rates predict mortality most accurately.
Significant discrepancy exists in the rate of disease progression when calculated with or without the initial time-point of reported symptom onset (26). It seems probable that symptoms of ALS may be noticeable by a patient (or family members, who often contribute to the estimation of disease onset in our experience) without causing any significant disability. Therefore the ALSFRS might lack sensitivity at the milder end of the disease spectrum. Conversely, it may be that significant disability milestones are rapidly attained in the middle stages of ALS (i.e. around the time of enrolment in the trial) without any acceleration of the disease process itself.

In the last stages of advanced disability, the ALSFRS might well ‘bottom out’ (27), although most clinical trials do not include these data; thus the imputation choice of zero to represent death remains necessarily arbitrary. FVC data correspondingly appeared to change little in last months before death (23) and were particularly prone to inaccuracy in the context of significant bulbar weakness (28).

Progression and survival in ALS have been modelled using a Weibull probability distribution (17,29), but since longitudinally extensive data...
demonstrate a plateau effect in mortality risk (Figure 8), previous investigators have resorted to a compound distribution (30), suggesting this model to have limited application. Untransformed data clearly demonstrate prolonged survival in a minority of patients (Figure 9).

Systematic reviews of prognostic factors in ALS have been performed with respect to both survival (31) and functional status (32). These factors overlap but are not identical; however, reliable models for prediction of function are limited by a relative paucity of replicated studies (6,7). The PRO-ACT database has already contributed greatly, for example, in confirming that higher baseline levels of serum urate and creatinine are independently associated with slower ALSFRS-R decline and longer survival (25), and in the formulation of a multivariate predictive model using Bayesian trees (33). Historical accounts of long-term survival in ALS noted a plateau in cumulative mortality around five years from disease onset (2,30), and these findings continue to be replicated in the modern era (4,34–36). Mortality remains the gold standard outcome measure for future ALS clinical trials, but inclusion of novel measures of function has been proposed (37) with the goal of addressing some of the documented inadequacies of the ALSFRS-R (38) and perhaps simultaneously accounting for the confounding impact of mortality (29).

The ALSFRS has been reported to misjudge disease severity when patients underestimate muscle function in contrast to objective examination (39). The relatively small time-span between assessments in clinical trials is also perhaps more prone to random error. It is also possible that cognitive impairment might contribute to an inaccurate recall of time-scale for symptom onset. The cognitive profile of ALS is typified by behavioural, executive and language dysfunction (40), but impairment of memory is also reported (41), and qualitatively distinct to that found in amnestic mild cognitive impairment (42). Inaccuracy of recall would adversely affect the prognostic value of symptom onset calculations but should not result in such systematically biased estimation of symptom duration.

An important future consideration would be whether rates of progression measured by alternative tools might be less susceptible to this symptom onset bias, thus potentially clarifying the bias inherent to the ALSFRS scale itself. Such analyses should include change in examination-based scales such as staging (43) and neurophysiological indices such as motor unit number estimation (MUNE), shown to be sensitive to more slowly-progressive disease (44). Alternative techniques to measure respiratory function in ALS have been assessed to outperform FVC in both sensitivity to detect deficits (45,46) and prognostication (47). They may, however, share some limitations (48,49), particularly since different respiratory abnormalities do not evolve simultaneously and also partially respond to therapeutic intervention (50).

This analysis meanwhile serves to remind of the potential for measurement techniques to bias the outcome of even the best-designed prospective interventional studies and reinforces the need for simultaneous assessment of more than one functional outcome measure (20), corroborated by multi-modal biomarker development (51).

Acknowledgements

The authors would like to thank the UKMND-LiCALs consortium for sharing the anonymised clinical data from the study.

MP is funded by a Wellcome Trust Research Training Fellowship.

MRT is funded by the Medical Research Council & Motor Neurone Disease Association UK Lady Edith Wolfson Senior Clinical Fellowship (MR/ K000780/1).

AAC receives salary support from the National Institute for Health Research (NIHR) Dementia Biomedical Research Unit and Biomedical Research Centre in Mental Health at South London and Maudsley NHS Foundation Trust and King’s College London.

This is an EU Joint Programme in Neurodegenerative Disease Research (JPND) project (STRENGTH, SOPHIA, ALS-CarE). The projects are supported through the following funding organizations under the aegis of JPND - www.jpnd.eu (United Kingdom, Medical Research Council and Economic and Social Research Council).

The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Declaration of interest: MRT has received consultancy payments from Biogen Idec, GSK, Vertex and Neuraltus Pharmaceuticals for expert opinion on the natural history, management and biomarker development in ALS. He is Commissioning Editor for the Journal of Neurology, Neurosurgery and Psychiatry, and external advisor to the Scientific Innovation Team of the Ontario Brain Institute. Other authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

References

1. Turner MR, Hardiman O, Benatar M, Brooks BR, Chio A, de Carvalho M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013;12:310–22.
2. Jablecki CK, Berry C, Leach J. Survival prediction in amyotrophic lateral sclerosis. Muscle Nerve. 1989;12:833–41.

3. Kihira T, Yoshida S, Okamoto K, Kazimoto Y, Ookawa M, Hama K, et al. Survival rate of patients with amyotrophic lateral sclerosis in Wakayama Prefecture, Japan, 1966 to 2005. J Neurol Sci. 2008;268:95–101.

4. Pupillo E, Messina P, Logroscino G, Beghi E. Long-term survival in amyotrophic lateral sclerosis: a population based study. Ann Neurol. 2014;75:287–97.

5. Kauffmann P, Levy G, Thompson JLP, Delbene ML, Battista V, Gordon PH, et al. The ALSFRS-R predicts survival time in an ALS clinic population. Neurology. 2005;64:38–43.

6. Watanabe H, Atsuta N, Nakamura R, Hirakawa A, Watanabe H, Ito M, et al. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontal Degener. 2015;16:230–6.

7. Mandrioli J, Biguzzi S, Guidi C, Sette E, Terlizzi E, Ravaso A, et al. Heterogeneity in ALSFRS-R decline and survival: a population based study in Italy. Neurol Sci. 2015. doi:10.1007/s10072-015-2343-6.

8. Turner MRM, Scaber J, Goodfellow JJ, Lord ME, Marsden R, Talbot K. The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis. J Neurol Sci. 2010;294:81–5.

9. Andersen PM, Nilsson P, Keränen ML, Forsgren L, Hägghund J, Karlsborg M, et al. Phenotypic heterogeneity in motor neuron disease patients with Cu/Zn-superoxide dismutase mutations in Scandinavia. Brain. 1997;120 (Pt 1):1723–37.

10. Simón-Sánchez J, Dopper EGP, Cohn-Hokke PE, Hukema RK, Nicolao N, Seelaar H, et al. The clinical and pathological phenotype of C9orf72 hexanucleotide repeat expansions. Brain. 2012;135:723–35.

11. Bowser R, Turner MR, Shefner J. Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations. Nat Rev Neurol. 2011;7:631–8.

12. Appel V, Stewart SS, Smith G, Appel SH. A rating scale for bulbar-onset amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol. 1987;22:328–33.

13. Armon C, Graves MC, Moses D, Forté DK, Sepulveda L, Darby SM, et al. Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis. Muscle Nerve. 2000;23:874–82.

14. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13–21.

15. Gordon PH, Cheng B, Salachas F, Pradat P-F, Bruneteau G, Corcia P, et al. Progression in ALS is not linear but is curvilinear. J Neurol. 2010;257:1713–17.

16. Chio A, Mora G, Leone M, Mazzini L, Cocito D, Giordana MT, et al. Early symptom progression rate is related to ALS outcome: a prospective population based study. Neurology. 2002;59:99–103.

17. Gomeni R, Fava M. Amyotrophic lateral sclerosis disease progression model. Amyotrophic Lateral Scler Frontotemporal Degener. 2014;15:119–29.

18. Kollewe K, Mauss U, Krampfl K, Petri S, Dengler R, Mohammadi B. ALSFRS-R score and its ratio: a useful predictor for ALS progression. J Neurol Sci. 2008;275:69–73.

19. Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66:265–7.

20. Traynor BJ, Zhang H, Shefner JM, Schoeneffeld D, Cudkowicz ME. Functional outcome measures as clinical trial endpoints in ALS. Neurology. 2004;63:1933–5.

21. Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2006;77:390–2.

22. Bensimon G, Lacomblez L, Meineigner V, Iso H. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330:585–91.

23. Stambler N, Charatan M, Cedarbaum JM. Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group. Neurology. 1998;50:66–72.

24. Pureishi M, Hayden D, Urbainelli L, Ferrante K, Newhall K, Myers D, et al. Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler. 2006;7:173–82.

25. Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology 2014;83:1719–25.

26. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995;118 (Pt 3):707–19.

27. Wicks P, Massagli MP, Wolf G, Heywood J. Measuring function in advanced ALS: Validation of ALSFRS-EX extension items. Eur J Neurol. 2009;16:353–9.

28. Ward NS, Hill NS. Pulmonary function testing in neuromuscular disease. Clin Chest Med. 2001;22:769–81.

29. Berry JD, Miller R, Moore DH, Cudkowicz ME, van den Berg LH, Keer D, et al. The Combined Assessment of Function and Survival (CAFS), a new endpoint for ALS clinical trials. Amyotrophic Lateral Scler Frontotemporal Degener. 2013;14:162–8.

30. Kondo K, Hemmi I. Clinical Statistics in 515 Fatal Cases of Motor Neuron Disease. Determinants of Cause. Neuroepidemiology. 1984;3:139–48.

31. Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10:310–23.

32. Creemers H, Grupstra H, Nollet F, van den Berg LH, Beelen A. Prognostic factors for the course of functional status of patients with ALS: a systematic review. J Neurol. 2014;1407–23.

33. Küffner R, Zach N, Norell R, Hawe J, Schoenfeld D, Wang L, et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol. 2015 Jan;33(1):51–7.

34. Lee CT-C, Chiu Y-W, Wang K-C, Hwang C-S, Lin K-H, Lee I-T, et al. ALSFRS and Appel ALS scores: discordance with disease progression: a prognostic biomarker in ALS. J Neurol Sci. 2015:jnnp – 2015–310998. doi:10.1136/jnnp-2015–310998.

35. Tramacere I, Dalla Bella E, Chio A, Mora G, Filippini G, Lauria G, et al. The MITOS system predicts long-term survival: A Population Based Study of 1149 Cases in Taiwan. J Epidemiol. 2013;23:35–40.

36. Jemmum P, Ilsen R, Pedersen SW, Kjellberg J. Mortality, health, social and economic consequences of amyotrophic lateral sclerosis: a controlled national study. J Neurol. 2013;260:785–93.

37. Labra J, Menon P, Byth K, Morrisson S, Vucic S. Rate of disease progression: a prognostic biomarker in ALS. J Neurol Neurosurg Psychiatry. 2015:2015–310998. doi:10.1136/jnp-2015–310998.

38. Voustianiouk A, Seidel G, Panchal J, Sivak M, Czaplinski A, Yen A, et al. ALSFRS and Appel ALS scores: discordance with disease progression. Muscle Nerve. 2008;37:668–72.
40. Goldstein LH, Abrahams S. Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol. 2013;12:368–80.

41. Mantovan MC, Baggio L, Dalla Barba G, Smith P, Pegoraro E, Soraru’ G, et al. Memory deficits and retrieval processes in ALS. Eur J Neurol. 2003;10:221–7.

42. Machts J, Bitter V, Kasper E, Schuster C, Prudlo J, Abdulla S, et al. Memory deficits in amyotrophic lateral sclerosis are not exclusively caused by executive dysfunction: a comparative neuropsychological study of amnestic mild cognitive impairment. BMC Neurosci. 2014;15:83.

43. Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012;135:847–52.

44. Felice KJ. A longitudinal study comparing thenar motor unit number estimates to other quantitative tests in patients with amyotrophic lateral sclerosis. Muscle Nerve. 1997;20:179–85.

45. Pinto S, Geraldes R, Vaz N, Pinto A, de Carvalho M. Changes of the phrenic nerve motor response in amyotrophic lateral sclerosis: longitudinal study. Clin Neurophysiol. 2009;120:2082–5.

46. Fitting JW, Paillex R, Hirt L, Aebischer P, Schluep M. Sniff nasal pressure: a sensitive respiratory test to assess progression of amyotrophic lateral sclerosis. Ann Neurol. 1999;46:887–93.

47. Capozzo R, Quaranta VN, Pellegrini F, Fontana A, Copetti M, Carratù P, et al. Sniff nasal inspiratory pressure as a prognostic factor of tracheostomy or death in amyotrophic lateral sclerosis. J Neurol. 2014;262:593–603.

48. Lyall RA, Donaldson N, Polkey MI, Leigh PN, Moxham J. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain. 2001;124:2000–13.

49. Chaudri MB, Liu C, Watson L, Jefferson D, Kinnear WJ. Sniff nasal inspiratory pressure as a marker of respiratory function in motor neuron disease. Eur Respir J. 2000;15:539–42.

50. Leonardis L, Dolenc Grosčelj L, Vidmar G. Factors related to respiration influencing survival and respiratory function in patients with amyotrophic lateral sclerosis: a retrospective study. Eur J Neurol. 2012;19:1518–24.

51. Turner MR, Benatar M. Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis. Muscle Nerve. 2015, Vol 51, Issue 1, Pages 14–8. doi:10.1002/mus.24470.

**Supplementary material available online**

**Supplementary Figures 1 and 2**